Rodman & Renshaw (RODM) Sells Aceras BioMed to BioMarin (BMRN) in $15M Transaction
More News related to BMRN
- Roth Capital Upgrades BioMarin Pharmaceutical (BMRN) to Buy
- Notable Analyst Rating Changes of the Day 02/08: HD, AMZN, ARAY, WGO Upgraded; BMRN, ARG, HK Downgraded
- Brean Murray Downgrades BioMarin Pharmaceutical (BMRN) to Hold; Valuation Call
- BioMarin Announces 2010 Guidance
- BioMarin to Acquire LEAD Therapeutics
More News related to RODM
- Rodman Reports Record 2009 Financial Results
- Rodman & Renshaw Capital Group Announces Results of Annual Stockholders Meeting
- Seanergy Maritime Holdings Corp. Announces Closing of Its $30 Million Common Stock Offering
- China Yongxin Pharmaceuticals, Inc. Engages Rodman & Renshaw, LLC as its Financial Advisor
- SORL Auto Parts, Inc. to Raise Approximately $10 Million in Registered Direct Offering
More News related to Mergers and Acquisitions
- Airgas (ARG) Rejects Air Products (APD) Takeover Bid
- Sony (SNE) Subsidiary Acquires iCyt Mission Tech
- Audiovox Corp. (VOXX) Acquires Assets of Invision Industries
- Morningstar (MORN) Buys Footnoted.org
- Volcano Corp. (VOLC) Acquires Xtract Catheter Device from Lumen Biomed
Rodman & Renshaw Capital Group, Inc. (NASDAQ: RODM) announced today that its affiliate, Aceras BioMedical LLC, has sold Huxley Pharmaceuticals Inc. to BioMarin Pharmaceutical Inc. (NASDAQ: BMRN). Huxley was established by Aceras in August 2008 with a focus on developing therapeutic products for rare diseases of the nervous system.
Under the terms of the agreement, BioMarin paid Huxley stockholders $15.0 million. An additional $7.5 million is payable upon the achievement of regulatory milestones. Further, Huxley stockholders may also receive up to an additional $36 million in milestone payments if certain annual, cumulative sales and U.S. development milestones are met. Aceras owned 95% of Huxley's stock at the time of the transaction.
Related Categories
Mergers and AcquisitionsStocks Mentioned
+0.00
-0.43Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
